BCL2L1 and B-cell chronic lymphocytic leukemia: The combination of venetoclax and sunitinib may also be worth investigating, based on the results of an in vitro study that found that sunitinib may overcome venetoclax resistance in some patients by downregulating BCL-xl, Mcl-1, and A1 in CLL cells [79].